NVCR News and Press, NovoCure Limited From 10/26/23

CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...

NovoCure Limited (NVCR) is expected to report $-0.51 for Q3 2023

2023-10-25 14:02:09 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth HC Wainwright cuts NovoC...

2023-10-18 10:31:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The third quarter was ...

Highlights include a new analysis showing that Tumor Treating Fields therapy, when added to standard systemic therapies, did not adversely affect patients’ quality of life in the phase 3 LUNAR clinical trial. Novocure (NASDAQ: NVCR) today announced its participation in the Eu...

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the thr...

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTField...

2023-09-19 10:15:00 ET Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR) , which makes a wearable device for treating cancer. The average investor might see NovoCure as yet another struggling cancer therapy co...

Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Ca...